(Q54198800)

26 May 2018

title

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. (English)

1 reference

26 May 2018

epithelioid inflammatory myofibroblastic sarcoma

main subject

inflammation

0 references

0 references

1 reference

Shiro Kimbara

1

1 reference

26 May 2018

Koji Takeda

2

1 reference

26 May 2018

Hiroko Fukushima

3

1 reference

26 May 2018

Toru Inoue

4

1 reference

26 May 2018

Hideaki Okada

5

1 reference

26 May 2018

Yumi Shibata

6

1 reference

26 May 2018

Utae Katsushima

7

1 reference

26 May 2018

Asuka Tsuya

8

1 reference

26 May 2018

Shinya Tokunaga

9

1 reference

26 May 2018

Haruko Daga

10

1 reference

26 May 2018

Takahiro Okuno

11

1 reference

26 May 2018

Takeshi Inoue

12

1 reference

26 May 2018

publication date

15 July 2014

1 reference

26 May 2018

Japanese Journal of Clinical Oncology

published in

1 reference

26 May 2018

volume

44

1 reference

26 May 2018

issue

9

1 reference

26 May 2018

page(s)

868-871

1 reference

26 May 2018

ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

ALKoma: a cancer subtype with a shared target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU069

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYU069

1 reference

26 May 2018

PubMed ID

25028698

1 reference

26 May 2018